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INTRODUCTION
•Many HIV therapies and second-generation 
antipsychotics (SGAs) are metabolized  by overlapping 
enzymatic pathways.
•SGAs and protease inhibitors (PIs) have significant 
metabolic adverse effect profiles. These risks are 
compounded with concomitant therapy, both due to 
additive adverse effects and as a result of the 
CYP3A4-mediated interaction between the classes 
resulting in increased serum SGA concentrations.1
•Clinical data and monitoring recommendations for 
metabolic syndrome and drug interactions indicate that 
caution must be exercised with concomitant use of 
SGAs and PIs.
•Data on the prevalence of patients at risk for such 
drug interactions and evaluation of preventative 
strategies are limited.
OBJECTIVES
•The goal of this study was to explore the incidence of
metabolic syndrome among patients on concurrent
SGA and PI therapy compared to SGA use with other
antiretroviral therapy (ART) and to evaluate current
risk management practices at an HIV clinic.
METHODS
Study Design: Retrospective chart review of a 
randomized selection of 58 patients taking ART and 
SGAs
Inclusion Criteria:
• Patient at OSU Internal Medicine Specialty Clinic 
• Concomitant SGA and HIV ART use for 6 
consecutive months between  August 31, 2015 to 
September 30, 2018 
Exclusion Criteria: 
• Change in class of ART during study period 
Procedures:
• Patient stratification categories included: (1) risk 
factors for metabolic syndrome, (2) ICD-10 metabolic 
syndrome diagnosis, (3) adherence to American 
Diabetes Association’s (ADA) monitoring guidelines2, 
and (4) medication adjustments. 
• Variations in results between ART classes were 
evaluated.
• OSU Center for Health Sciences Institutional Review 
Board approved this study.
Statistical Tests:
• Descriptive statistics were conducted to assess 
abovementioned parameters. 
•This study highlighted the need for the 
development of a system to identify patients who 
need closer monitoring for and management of 
metabolic syndrome.
•Protease inhibitors are expected to carry the 
greatest risk of hyperlipidemia, diabetes, weight 
gain, and other adverse effects. These risks are 
compounded by concomitant SGA use. Of patients 
with metabolic syndrome, fifteen of thirty-four (44%) 
were taking protease inhibitors. Those who gained 
the most weight were taking a regimen that included 
a PI.
•None of the patients who met criteria for metabolic 
syndrome had a corresponding ICD-10 code listed.
•Most patients’ psychiatric medications are 
managed by psychiatrists and coordinating care can 
be difficult. However, it may be possible to improve 
monitoring and communication with patients’ 
psychiatrists when patients are at risk for metabolic 
disease states. Additionally, ART changes may be 
warranted to prevent potential long-term 
consequences of SGA and PI use.
•Another obstacle to improving monitoring is the 
lack of  insurance coverage for more frequent 
laboratory testing. 
•Until these barriers can be overcome, adequate 
treatment of comorbid conditions and lifestyle 
modification education will be especially important. 
Second Generation Antipsychotics Prescribed (n=58)
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Recorded Baseline Comorbidities (n=58)
Fasting Lipid Panel Weight Blood Pressure Fasting Plasma Glucose
Monitored Baseline 12 Weeks Baseline 4 Weeks 8 Weeks 12 Weeks Every 3 Months Baseline 12 Weeks Annual Baseline 12 Weeks Annual
Yes 27.6 6.9 67.2 15.5 20.7 39.7 55.2 58.6 50 91.4 46.6 39.7 84.5
No 53.4 75.9 22.4 69 63.8 46.6 44.8 29.3 37.9 8.6 39.7 46.6 15.5
Unknown 19 17.2 10.3 15.5 15.5 13.8 0 12.1 12.1 0 13.8 13.8 0
Percentage of Patients Monitored Per ADA Recommendations2 for Patients Taking SGAs (n=58) 
One goal of this study was to evaluate the 
prevalence of preexisting risk factors among 
patients who are at an increased risk of 
developing metabolic syndrome with SGA use, 
especially those on ART that may contribute to 
this risk. As reflected in the graph, a significant 
proportion of patients were lacking this 
information either because it was not recorded  
or was missing from the current electronic 
record. 
•Patient baseline information that was recorded 
prior to the transition to the Epic EHR system 
was not available for review and was marked 
“unknown”. 
A majority of patients were found 
to be taking  SGAs, such as 
quetiapine and olanzapine, that 
pose the greatest risk of metabolic 
effects. 
•Of those taking SGAs that have 
specific dose adjustment 
recommendations when given 
with PIs and cobicistat, only 3 out 
of 34 (8.8%) SGAs were dosed 
appropriately. 
•One patient was receiving a 
contraindicated regimen of 
lurasidone and a protease 
inhibitor. 
No patients were monitored per ADA guidelines. 
• Of the fifty-eight patients studied, twenty (34.5%) met criteria for metabolic syndrome and were in need of closer monitoring. Eight (13.8%) 
did not have adequate monitoring history to make a determination. 
•The ADA also recommends monitoring waist circumference; however, this measurement is not taken at the clinic. 
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